/EPRX.TO

EPRX.TO Stock - Eupraxia Pharmaceuticals Inc.

Q: What is the analyst price target for EPRX.TO?

Analyst price target information is not currently available for EPRX.TO.

Q: What is EPRX.TO's market cap?

Market capitalization information is not currently available for EPRX.TO.

Healthcare|Biotechnology|TSX

$9.70+6.48%

+$0.59 (+6.48%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $10.67

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EPRX.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.50

52W High$10.10

52W Low$3.96

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-235,248	$-209,911	$-193,273	$-111,529	$-116,809
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-36,993,635	$-36,896,743	$-22,634,607	$-20,872,426	$-2,245,766
Net Income	$-34,937,494	$-37,391,708	$-23,259,373	$-22,989,606	$-3,997,202
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.03	$-1.58	$-1.21	$-1.61	$-0.31

Company Overview

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Visit Website

Earnings History & Surprises

EPRX.TO

Beat Rate

53%

Last 17 quarters

Avg Surprise

-2.6%

EPS vs Estimate

Beats / Misses

9/6

2 met exactly

Latest EPS

$-0.24

Q4 2025

EPS Surprise History

Q1 24

-58.3%

$-0.38vs$-0.24

Q2 24

-58.3%

$-0.38vs$-0.24

Q3 24

0.0%

$-0.23vs$-0.23

Q4 24

-21.1%

$-0.23vs$-0.19

Q1 25

-75.0%

$-0.28vs$-0.16

Q2 25

-30.4%

$-0.30vs$-0.23

Q3 25

+3.8%

$-0.24vs$-0.25

Q4 25

-26.1%

$-0.24vs$-0.19

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 4, 2025	$-0.19	$-0.24	-26.1%	✗ MISS
Q3 2025	Aug 12, 2025	$-0.25	$-0.24	+3.8%	✓ BEAT
Q2 2025	May 6, 2025	$-0.23	$-0.30	-30.4%	✗ MISS
Q1 2025	Mar 20, 2025	$-0.16	$-0.28	-75.0%	✗ MISS
Q4 2024	Nov 7, 2024	$-0.19	$-0.23	-21.1%	✗ MISS
Q3 2024	Aug 7, 2024	$-0.23	$-0.23	0.0%	= MET
Q2 2024	Apr 1, 2024	$-0.24	$-0.38	-58.3%	✗ MISS
Q1 2024	Mar 21, 2024	$-0.24	$-0.38	-58.3%	✗ MISS
Q4 2023	Nov 14, 2023	$-0.32	$-0.25	+21.9%	✓ BEAT
Q3 2023	Aug 11, 2023	$-0.36	$-0.36	0.0%	= MET
Q2 2023	May 11, 2023	$-0.36	$-0.23	+36.1%	✓ BEAT
Q1 2023	Mar 23, 2023	$-0.43	$-0.41	+4.7%	✓ BEAT
Q4 2022	Nov 7, 2022	$-0.43	$-0.22	+49.4%	✓ BEAT
Q3 2022	Aug 12, 2022	$-0.38	$-0.31	+19.5%	✓ BEAT
Q1 2022	Mar 31, 2022	$-0.34	$-0.26	+23.8%	✓ BEAT
Q1 2022	Mar 29, 2022	$-0.42	$-0.27	+35.7%	✓ BEAT
Q4 2021	Nov 10, 2021	—	$-0.35	—	—
Q3 2021	Aug 13, 2021	$-0.55	$-0.38	+30.9%	✓ BEAT
Q1 2021	Mar 30, 2021	—	$-1.13	—	—
Q1 2021	Mar 3, 2021	—	$-0.08	—	—

Frequently Asked Questions about EPRX.TO

What is EPRX.TO's current stock price?

Eupraxia Pharmaceuticals Inc. (EPRX.TO) is currently trading at $9.70 per share. The stock has moved +6.48% today.

What is the analyst price target for EPRX.TO?

No analyst price targets are currently available for this stock.

What sector is Eupraxia Pharmaceuticals Inc. in?

Eupraxia Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.

What is EPRX.TO's market cap?

Eupraxia Pharmaceuticals Inc. has a market capitalization of $0.35 billion, making it a small-cap company.

Does EPRX.TO pay dividends?

No, Eupraxia Pharmaceuticals Inc. does not currently pay a dividend to shareholders.